Abstract
Hemophilia B, or factor IX deficiency, is an X-linked recessive disorder occurring in about 1 in 25,000 males. Affected individuals are at risk for spontaneous bleeding into many organs; treatment mainly consists of the transfusion of clotting factor concentrates prepared from human blood or recombinant sources after bleeding has started. Small- and large-animal models have been developed and/or characterized that closely mimic the human disease state. As a preclinical model for gene therapy, recombinant adeno-associated viral vectors containing the human or canine factor IX cDNAs were infused into the livers of murine and canine models of hemophilia B, respectively. There was no associated toxicity with infusion in either animal model. Constitutive expression of factor IX was observed, which resulted in the correction of the bleeding disorder over a period of over 17 months in mice. Mice with a steady-state concentration of 25% of the normal human level of factor IX had normal coagulation. In hemophilic dogs, a dose of rAAV that was approximately 1/10 per body weight that given to mice resulted in 1% of normal canine factor IX levels, the absence of inhibitors, and a sustained partial correction of the coagulation defect for at least 8 months.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Lin, H.-F., Maeda, N., Smithies, O., Straight, D.L. & Stafford, D.W. A Coagulation Factor IX-Deficient Mouse Model for Human Hemophilia B. Blood 90, 3962â 3966 (1997).
Bi, L. et al. Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A. Nature Gen. 10, ( 1995).
Wang, L. et al. A factor IX-deficient mouse model for hemophilia B gene therapy. Med. Sci. 94, 11563â11566 (1997).
Kundu, R.K. et al. Targeted Inactivation of the Coagulation Factor IX Gene Causes Hemophilia B. in Mice. Blood 92, 68â 174 (1998).
Nichols, T.C. et al. The roles of von Willebrand factor and factor VIII in arterial thrombosis: studies in canine von Willebrand disease and hemophilia A. Blood 81, 2644â2651 ( 1993).
Giles, A.R., Tinlin, S. & Greenwood, R. A canine model of hemophilic (factor VIII:C deficiency) bleeding. Blood 60, 727â 730 (1982).
Kingdon, H.S. & Hassell, T.M. Hemophilic dog model for evaluating therapeutic effectiveness of plasma protein fractions. Blood 58, 868â872 (1981).
Mauser, A.E., Whitlark, J. Whitney, K.M. & Lothrop, Jr., C.D. A deletion mutation causes hemophilia B in Lhasa Apso dogs. Blood 88, 3451â3455 (1996).
Brinkhous, K.M. et al. Pharmacokinetics and pharmacodynamics of a B-domain deleted recombinant factor VIII derivative, r-VIII SQ, in canine hemophilia. Thromb. Haemost. 69, 852 (1993 ).
Griggs, T.R., Webster, W.P., Cooper, H.A., Wagner, R.H. & Brinkhous, K.M. Von Willebrand Factor: Gene dosage relationships and transfusion response in bleeder swine - a new bioassay. Proc. Natl. Acad. Sci. USA 71, 2087â 2090 (1974).
Neuenschwander, S. & Pliska, V. 1994. Factor VIII in blood plasma of haemophilic sheep: analysis of clotting time-plasma dilution curves. Haemostasis 24, 27â 35 (1994).
Dai, Y. et al. Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: Tolerization of factor IX and vector antigens allows for long-term expression. Med. Sci. 92, 1401â 1405 (1995).
Herzog, R.W. et al. Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus. Proc. Natl. Acad. Sci. USA 94, 5804â 5809 (1997).
Yao, S.N., Smith, K.J. & Kurachi, K. Primary myoblast-mediated gene transfer: persistent expression of human factor IX in mice. Gene Ther. 1 , 99â107 (1994).
Yao, S.N., & Kurachi, K. Expression of human factor IX in mice after injection of genetically modified myoblasts. Proc. Natl. Acad. Sci. USA 89, 3357â3361 (1992).
Rosenberg, J.B. et al. Intracellular trafficking of factor VIII to von Willebrand factor granules. J. Clin. Invest. 101, 613 â624 (1998).
Ewenstein, B.M. et al. Nephrotic syndrome as a complication of immune tolerance in hemophilia B. Blood 89, 1115â 1116 (1997).
Warrier, I. et al. Factor IX inhibitors and anaphylaxis in hemophilia B. J. Pediatr. Hematol. Oncol. 19, 23-27 (1997).
Smith, T.A. et al. Adenovirus mediated expression of therapeutic plasma levels of human factor IX in mice. Nature Genet. 5, 397â402 (1993).
Kung, S.-H. et al. Human Factor IX Corrects the Bleeding Diathesis of Mice with Hemophilia B. Blood 91, 784â790.
Kay, M.A. et al. In vivo hepatic gene therapy: complete albeit transient correction of factor IX deficiency in hemophilia B dogs. Proc. Natl. Acad. Sci. USA 91, 2353â2357 (1994).
Kay, M.A. et al. In vivo gene therapy of hemophilia B: sustained partial correction in factor IX-deficient dogs. Science 262 , 117â119 (1993).
Snyder, R.O. et al. Persistent and therapeutic concnetrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors. Nature Genet. 16, 270-275 ( 1997).
Miao, C.H. et al. The kinetics of rAAV integration in the liver. Nature Genet. 19, 13â15 (1998).
Nakai, H. et al. Adeno-associated viral vector-mediated gene transfer of human blood coagulation factor IX into mouse liver. Blood 91, 4600â4607 (1998).
Brinkhous, K.M., Landen, C.N. & Read, M.S. Evaluation of sensitivity of whole blood clotting time (WBCT), partial thromboplastin time (PTT), and F.IX one-stage bioassay tests with low plasma F.IX levels observed with transfusion or gene therapy in canine hemophilia B. Blood 82, suppl 1 :592a (1993).
Samulski, R.J., Chang, L.-S. & Shenk, T. Helper-free stocks of recombinant adeno-associated viruses: Normal intergation does not require viral gene expression. J. Virol. 63, 3822â3828 ( 1989).
Dranoff, G. et al. Vaccination with irridated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulate potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA 90, 3539â3543 ( 1993).
Zolotukhin, S., Potter, M., Hauswirth, W.W., Guy, J. & Muzyczka, N. A "humanized" green fluorescent protein cDNA adapted for high-level gene expression in mammalian cells. J. Virol. 70, 4646â4654 (1996).
Li, J., Samulski, R.J. & Xiao, X. Role for highly regulated rep gene expression in adeno-associated virus vector production. J. Virol. (in the press).
Kasper, C.K. & Pool, J.G. Measurement of milid factor VIII inhibitors in Bethesda units. Thromb. Diathesis Haemorrhagica 34, 875â876 (1975).
Acknowledgements
We thank S. Powell, V. Vimal, B. Winther, B. Kaspar, T. Dull, D. Colvin, R. Lazar, M. Moskalenko, Y.-L. Li, R. Raymer and P. McElveen for technical assistance, and L. Naldini for comments. This work was supported by NIH grants, HL53682 (M.A.K.) and HL01648 (U.N.C.).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Snyder, R., Miao, C., Meuse, L. et al. Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors. Nat Med 5, 64â70 (1999). https://doi.org/10.1038/4751
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/4751
This article is cited by
-
Perioperative Management of Hemophilia Patients
Current Anesthesiology Reports (2024)
-
CRISPR somatic genome engineering and cancer modeling in the mouse pancreas and liver
Nature Protocols (2022)
-
Gene Therapy for Hemophilia: Progress to Date
BioDrugs (2018)
-
Ultrasound-targeted hepatic delivery of factor IX in hemophiliac mice
Gene Therapy (2016)
-
Successful attenuation of humoral immunity to viral capsid and transgenic protein following AAV-mediated gene transfer with a non-depleting CD4 antibody and cyclosporine
Gene Therapy (2012)